Corient Private Wealth LLC Sells 1,552 Shares of IDEXX Laboratories, Inc. $IDXX

Corient Private Wealth LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,625 shares of the company’s stock after selling 1,552 shares during the quarter. Corient Private Wealth LLC’s holdings in IDEXX Laboratories were worth $77,634,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in IDXX. Beacon Investment Advisory Services Inc. lifted its holdings in shares of IDEXX Laboratories by 11.9% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after buying an additional 6,710 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after acquiring an additional 8,845 shares in the last quarter. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $1,966,000. Diversified Trust Co. increased its position in IDEXX Laboratories by 223.5% during the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after acquiring an additional 2,901 shares during the period. Finally, Mirabella Financial Services LLP increased its position in IDEXX Laboratories by 156.2% during the third quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock worth $2,806,000 after acquiring an additional 2,683 shares during the period. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX stock opened at $562.09 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The firm has a market cap of $44.34 billion, a P/E ratio of 41.39, a P/E/G ratio of 3.07 and a beta of 1.55. The company’s 50-day moving average price is $561.66 and its two-hundred day moving average price is $620.91.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the business posted $2.91 EPS. The company’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on IDXX. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. UBS Group decreased their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Finally, Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.